Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Goodchild

Showing results (61-70 of 66) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 66 results.
Mayo Clinic Proceedings. Digital Health|June 26, 2025
CF Tummy Tracker: A Cystic Fibrosis-Specific Patient-Reported Outcome Measure for Daily Gastrointestinal Symptom BurdenRebecca J Calthorpe, Hisham A Saumtally, Laura M Howells, et al.
Cell Reports|September 21, 2018
Selective Na<sub>V</sub>1.7 Antagonists with Long Residence Time Show Improved Efficacy against Inflammatory and Neuropathic PainGirish Bankar, Samuel J Goodchild, Sarah Howard, et al.
Journal of Medicinal Chemistry|September 19, 2019
Identification of CNS-Penetrant Aryl Sulfonamides as Isoform-Selective Na<sub>V</sub>1.6 Inhibitors with Efficacy in Mouse Models of EpilepsyThilo Focken, Kristen Burford, Michael E Grimwood, et al.
British Journal of Pharmacology|June 26, 2024
The contribution of Na<sub>V</sub>1.6 to the efficacy of voltage-gated sodium channel inhibitors in wild type and Na<sub>V</sub>1.6 gain-of-function (GOF) mouse seizure controlJames P Johnson, Thilo Focken, Parisa Karimi Tari, et al.
Journal of Medicinal Chemistry|May 9, 2018
Design of Conformationally Constrained Acyl Sulfonamide Isosteres: Identification of N-([1,2,4]Triazolo[4,3- a]pyridin-3-yl)methane-sulfonamides as Potent and Selective hNa<sub>V</sub>1.7 Inhibitors for the Treatment of PainThilo Focken, Sultan Chowdhury, Alla Zenova, et al.
Elife|March 2, 2022
NBI-921352, a first-in-class, Na<sub>V</sub>1.6 selective, sodium channel inhibitor that prevents seizures in <i>Scn8a</i> gain-of-function mice, and wild-type mice and ratsJ P Johnson, Thilo Focken, Kuldip Khakh, et al.
Pageof 7

Showing results (61-70 of 66) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 66 results.
Mayo Clinic Proceedings. Digital Health|June 26, 2025
CF Tummy Tracker: A Cystic Fibrosis-Specific Patient-Reported Outcome Measure for Daily Gastrointestinal Symptom BurdenRebecca J Calthorpe, Hisham A Saumtally, Laura M Howells, et al.
Cell Reports|September 21, 2018
Selective Na<sub>V</sub>1.7 Antagonists with Long Residence Time Show Improved Efficacy against Inflammatory and Neuropathic PainGirish Bankar, Samuel J Goodchild, Sarah Howard, et al.
Journal of Medicinal Chemistry|September 19, 2019
Identification of CNS-Penetrant Aryl Sulfonamides as Isoform-Selective Na<sub>V</sub>1.6 Inhibitors with Efficacy in Mouse Models of EpilepsyThilo Focken, Kristen Burford, Michael E Grimwood, et al.
British Journal of Pharmacology|June 26, 2024
The contribution of Na<sub>V</sub>1.6 to the efficacy of voltage-gated sodium channel inhibitors in wild type and Na<sub>V</sub>1.6 gain-of-function (GOF) mouse seizure controlJames P Johnson, Thilo Focken, Parisa Karimi Tari, et al.
Journal of Medicinal Chemistry|May 9, 2018
Design of Conformationally Constrained Acyl Sulfonamide Isosteres: Identification of N-([1,2,4]Triazolo[4,3- a]pyridin-3-yl)methane-sulfonamides as Potent and Selective hNa<sub>V</sub>1.7 Inhibitors for the Treatment of PainThilo Focken, Sultan Chowdhury, Alla Zenova, et al.
Elife|March 2, 2022
NBI-921352, a first-in-class, Na<sub>V</sub>1.6 selective, sodium channel inhibitor that prevents seizures in <i>Scn8a</i> gain-of-function mice, and wild-type mice and ratsJ P Johnson, Thilo Focken, Kuldip Khakh, et al.
Pageof 7